FIELD: medicine, organic chemistry. SUBSTANCE: invention relates to inhibitor of intima hypertrophy. Inhibitor has hydroxyindole derivative as an active component of the formula (I) or its salt where R′ means hydrogen atom, phenyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxyl group, amino-group, lower alkylamino-group or halogen atom, or pyridyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxyl group, amino-group, lower alkylamino-group, halogen atom, lower alkoxycarbonyl group or carboxyl group; phenyl group that can be substituted with, or pyridyl group that can be substituted with lower alkyl group, lower alkoxy-group, lower alkylaminoalkoxy-group, hydroxy-group, amino-group, lower alkylamino-group, halogen atom, lower alkoxycarbonyl-group or carboxyl group; hydrogen atom, lower alkyl group, benzyl group or benzenesulfonyl group that can be substituted or acyl group; hydrogen atom, lower alkoxy-group, halogen atom, amino-group, lower alkylamino-group, carboxyl group, lower alkoxycarbonyl group, phenylcarbamyl group that can be substituted, or trifluoromethyl group; CH-group or means the whole number from 0 to 4 that means a number of substituents and double dotted/ /unbroken line means a simple bond or a double bond. Agent shows the strong inhibitory effect directed against intima hypertrophy and used as an agent for prophylaxis/treatment/ /relaxation of proliferative vascular diseases as, for example, restenosis after PTCA, arteriosclerosis, peripheral embolia and angiitis. Invention relates to also the use of hydroxyindole derivative for synthesis of inhibitor of intima hypertrophy, composition for inhibition of intima hypertrophy and the method of prophylaxis and treatment of patients with intima hypertrophy. Described inhibitor is the effective agent used for prophylaxis of vessel restenosis after angioplasty and for treatment of patients with arteriosclerosis. EFFECT: enhanced effectiveness of inhibitor described above. 9 cl, 2 dwg, 24 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
NAPHTHALENE DERIVATIVES AND METHOD OF PREPARATION THEREOF | 1996 |
|
RU2129120C1 |
METHOD OF OBTAINING 4-NITROIMIDAZOLE COMPOUND | 2005 |
|
RU2345071C2 |
DERIVATIVES OF PYRIDAZINE, MEDICINAL AGENTS BASED ON THEREOF AND METHOD FOR TREATMENT OF ARTHRITIS | 1998 |
|
RU2209813C2 |
CYCLIC AMINE COMPOUND | 2005 |
|
RU2379307C2 |
INDOLE DERIVATIVE | 1995 |
|
RU2137759C1 |
INDANE CONDENSED DERIVATIVES, METHOD OF THEIR SYNTHESIS AND COMPOSITION SHOWING ANTITUMOR EFFECT | 1995 |
|
RU2124017C1 |
DERIVATIVE OF 2-ARYL-8-OXODIHYDROPURINE, METHOD FOR ITS PREPARING, PHARMACEUTICAL COMPOSITION AND AGENT COMPRISING THEREOF, INTERMEDIATE COMPOUND | 1998 |
|
RU2223272C2 |
APPLICATION OF BENZOPHENOL DERIVATIVE OR ITS SALT AND TNF-α INHIBITOR IN COMBINATION, AND PHARMACEUTICAL COMPOSITION, CONTAINING THEREOF OR ITS SALT AND INHIBITOR | 2009 |
|
RU2522272C2 |
PYRIDAZINONE DERIVATIVES AND METHODS OR PREPARING THEREOF | 1996 |
|
RU2131419C1 |
ACETAMIDE DERIVATIVES (VARIANTS), METHOD OF PREPARATION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION AND AGENT | 1996 |
|
RU2160256C2 |
Authors
Dates
2000-02-27—Published
1997-01-16—Filed